Research Description

Our laboratory investigates the structural and functional basis of molecular recognition in infectious diseases and cancer to advance the development of next-generation vaccines, antibody therapeutics, and protein-based medicines.

We integrate structural biology, protein engineering, immunology, and virology to define the molecular organization, conformational dynamics, and mechanistic principles underlying viral glycoprotein-mediated entry, immune recognition, and antibody-mediated protection. Using cryo-electron microscopy, virological assays, biochemical and biophysical approaches, and antibody discovery platforms, we characterize the molecular architecture of viral glycoproteins and uncover how structural transitions, receptor engagement, and antibody recognition regulate viral infection and immune defense. These insights provide a foundation for the rational design of stabilized vaccine immunogens, broadly neutralizing antibodies, nanobody therapeutics, and receptor-based antiviral strategies.

In parallel, we apply the same structure-guided approaches to immuno-oncology by investigating the molecular mechanisms that regulate immune checkpoint signaling and tumor immune evasion. We engineer therapeutic antibodies and multispecific protein biologics targeting cancer-associated antigens and immune modulatory receptors to enhance anti-tumor immunity and improve the precision and efficacy of cancer immunotherapy.

Our research bridges fundamental structural biology with translational immunology through the integration of computational protein design, structure-guided antigen engineering, antibody discovery, and functional evaluation in vitro and in vivo. By translating mechanistic insights into innovative vaccines, antibody therapeutics, and engineered protein biologics, we aim to develop broadly effective interventions against infectious diseases and cancer while advancing our fundamental understanding of molecular recognition and immune regulation.